Veracyte, Inc. (VCYT)
Automate Your Wheel Strategy on VCYT
With Tiblio's Option Bot, you can configure your own wheel strategy including VCYT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VCYT
- Rev/Share 6.2895
- Book/Share 15.9754
- PB 2.3624
- Debt/Equity 0.0322
- CurrentRatio 6.2261
- ROIC 0.0186
- MktCap 2983315789.0
- FreeCF/Share 1.2475
- PFCF 30.3769
- PE 98.0007
- Debt/Assets 0.0296
- DivYield 0
- ROE 0.025
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | VCYT | Morgan Stanley | -- | Underweight | -- | $48 | Dec. 2, 2025 |
| Initiation | VCYT | Canaccord Genuity | -- | Hold | -- | $40 | Oct. 20, 2025 |
| Initiation | VCYT | Craig Hallum | -- | Buy | -- | $45 | March 20, 2025 |
| Downgrade | VCYT | Goldman | Buy | Neutral | $38 | $37 | Dec. 5, 2024 |
| Initiation | VCYT | UBS | -- | Buy | -- | $43 | Oct. 16, 2024 |
| Initiation | VCYT | Guggenheim | -- | Buy | -- | $40 | Oct. 10, 2024 |
News
Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Veracyte, Inc. (NASDAQ:VCYT ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Shayla Gorman - Senior Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research, LLC Mason Carrico - Stephens Inc. Puneet Souda - Leerink Partners Maggie Boeye - William Blair & Company Lu Li - UBS Group AG Corey Rosenbaum - Scotiabank Subbu Nambi - Guggenheim Securities, LLC Yuko Oku - Morgan Stanley Joseph Conway - Needham & Company, LLC Prashant Kota - Goldman Sachs Operator Good day, and …
Read More
Veracyte to Participate in Upcoming Investor Conferences
Published: February 19, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 46th Annual Institutional Investors Conference – Orlando, FL Presentation on March 5th at 9:50 a.m. Eastern Time Leerink Partners Global Healthcare Conference – Miami, FL Fireside Chat on March 11th at 8:40 a.m. Eastern Time Live audio webcasts of the company's presentations will be available by.
Read More
New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
Published: February 14, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research.
Read More
Best Momentum Stocks to Buy for February 13th
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
VCYT and NTRS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 13, 2025.
Read More
New Strong Buy Stocks for February 13th
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
SYF, SSB, VCYT, DAWN and FISI have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2025.
Read More
About Veracyte, Inc. (VCYT)
- IPO Date 2013-10-30
- Website https://www.veracyte.com
- Industry Biotechnology
- CEO Marc A. Stapley
- Employees 824